The Health Technology Assessment Review options paper includes a line that explains why any stakeholder push to widen how technologies are valued faces such strong institutional resistance.
'A broader assessment of value would increase the cost and reduce the benefit to us'
February 6, 2024 Latest NewsBioPharmaCommentLatest Video
New Stories
-
Pharmac announces expanded access to three cancer medicines
October 11, 2024 - - Latest News -
Novartis-led partnership says heart health shouldn't be dependent on where you live
October 11, 2024 - - Latest News -
Bondi Junction response must include increased funding and support for severe mental illness
October 11, 2024 - - Latest News -
New report unveils hidden cost of Alzheimer’s disease, with cases to double by 2050
October 10, 2024 - - Latest News -
Amplia Therapeutics CEO shares Prime Minister's Prize for Innovation
October 10, 2024 - - Latest News -
Healthy Bones Australia calls for greater Government commitment to bone health
October 9, 2024 - - Latest News -
TGA approves new indication for Telix’s Illuccix to include patient selection for PSMA-targeted therapy
October 9, 2024 - - Australian Biotech